<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742051</url>
  </required_header>
  <id_info>
    <org_study_id>50102016015</org_study_id>
    <nct_id>NCT02742051</nct_id>
  </id_info>
  <brief_title>A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer</brief_title>
  <official_title>A Randomised Pilot Study of Neoadjuvant Everolimus Plus Letrozole Compared With FEC in Postmenopausal Patients With ER-positive, HER2-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open, randomized pilot feasibility trial is to evaluate the feasibility and effect of&#xD;
      neoadjuvant everolimus plus letrozole versus neoadjuvant fluorouracil, epirubicin plus&#xD;
      cyclophosphamide (FEC) in treating postmenopausal women with ER-positive, HER2-negative&#xD;
      breast cancer. Forty postmenopausal stage M0, ER-positive, HER2-negative invasive breast&#xD;
      cancer women who had a primary tumor &gt; 2cm by imaging or an axillary lymph node &gt; 2cm by&#xD;
      imaging were randomly (1:1) enrolled to receive neoadjuvant everolimus plus letrozole for 18&#xD;
      weeks or neoadjuvant FEC for 6 cycles before surgery. The primary objective is to determine&#xD;
      the feasibility of neoadjuvant everolimus plus letrozole in postmenopausal patients with&#xD;
      ER-positive, HER2-negative breast cancer. Secondary aims are to compare the ultrasound&#xD;
      response rate, pathological complete response (pCR) rate, breast-conserving surgery rate,&#xD;
      toxicities, and changes in the percentages or counts of peripheral blood CD4+ T cells, CD8+ T&#xD;
      cells, tumor-specific CTLs, T helper cells (Th), regulatory T cells (Treg), and NK cells and&#xD;
      changes in tumor Ki67 index (pre- versus post- neoadjuvant therapy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">March 14, 2020</completion_date>
  <primary_completion_date type="Actual">March 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the trial</measure>
    <time_frame>during on-neoadjuvant therapy period (defined as the period from the first dose of study medication up to 30 days of the last dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrasound response rate</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR) rate</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast-conserving surgery rate</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>during on-neoadjuvant therapy period (defined as the period from the first dose of study medication up to 30 days of the last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood CD8+ T cell percentage change in relation to neoadjuvant therapy</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood T helper cell percentage change in relation to neoadjuvant therapy</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood regulatory T cell percentage change in relation to neoadjuvant therapy</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood NK cell percentage change in relation to neoadjuvant therapy</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood tumor-specific CTLs count change in relation to neoadjuvant therapy</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood CD4+ T cell percentage change in relation to neoadjuvant therapy</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Ki67 index change in ralation to neoadjuvant therapy</measure>
    <time_frame>at definitive surgery (18-20 weeks after the first dose of study medication)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus+Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus 10mg/d,po + letrozole 2.5mg/d,po * 18 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluorouracil+epirubicin+cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 * 6 cycles (every 21 days per cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Neoadjuvant endocrine therapy</description>
    <arm_group_label>Everolimus+Letrozole</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Neoadjuvant endocrine therapy</description>
    <arm_group_label>Everolimus+Letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Neoadjuvant chemotherapy</description>
    <arm_group_label>Fluorouracil+epirubicin+cyclophosphamide</arm_group_label>
    <other_name>5-Fu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Neoadjuvant chemotherapy</description>
    <arm_group_label>Fluorouracil+epirubicin+cyclophosphamide</arm_group_label>
    <other_name>EPB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Neoadjuvant chemotherapy</description>
    <arm_group_label>Fluorouracil+epirubicin+cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patients signed the written informed consent&#xD;
&#xD;
          -  The patients present with non-metastatic unilateral invasive ER-positive,&#xD;
             HER2-negative breast cancer with a primary breast tumor &gt; 2cm by imaging or an&#xD;
             axillary lymph node &gt; 2cm by imaging.&#xD;
&#xD;
          -  Postmenopausal women with age less than 70 years old.&#xD;
&#xD;
          -  The patients have no history of hormone therapy, chemotherapy, breast cancer surgery&#xD;
             and radiotherapy.&#xD;
&#xD;
          -  The patients have normal cardiac functions by echocardiography.&#xD;
&#xD;
          -  The patients' ECOG scores are ≤2.&#xD;
&#xD;
          -  The patients can swallow pills.&#xD;
&#xD;
          -  The results of patients' blood tests are as follows:&#xD;
&#xD;
               -  Hb≥90g/L;&#xD;
&#xD;
               -  WBC≥4E+9/L;&#xD;
&#xD;
               -  Plt≥100E+9/L;&#xD;
&#xD;
               -  Neutrophils≥1.5E+9/L;&#xD;
&#xD;
               -  ALT and AST ≤ triple of normal upper limit;&#xD;
&#xD;
               -  TBIL ≤ 1.5 times of normal upper limit;&#xD;
&#xD;
               -  Creatinine ≤ 1.5 times of normal upper limit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patients have other cancers at the same time or have the history of other cancers&#xD;
             except controlled skin basal cell carcinoma or skin squamous cell carcinoma or&#xD;
             carcinoma in situ of cervix uterus;&#xD;
&#xD;
          -  The patients have active infections that were not suitable for chemotherapy;&#xD;
&#xD;
          -  The patients have severe non-cancerous diseases.&#xD;
&#xD;
          -  The patients have bilateral breast cancers or multifocal breast cancers or&#xD;
             inflammatory breast cancers.&#xD;
&#xD;
          -  The patients have a history of previous treatment with mTOR inhibitors.&#xD;
&#xD;
          -  The patients are undergoing current administration of anti-cancer therapies, or are&#xD;
             attending other clinical trials.&#xD;
&#xD;
          -  The patients are in some special conditions that they cannot understand the written&#xD;
             informed consent, such as they are demented or hawkish.&#xD;
&#xD;
          -  The patients have allergic history or contraindication of any of the interventional&#xD;
             drugs.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieqiong Liu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Breast Tumor Center, Sun Yat-sen Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jieqiong Liu, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Attending Surgeon of Breast Tumor Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

